Related Experiment Videos
Sezolamide: additivity to timolol twice daily
F Gunning1, A Béchetoille, E A Lippa
1Glaucoma Centre, Academic Medical Centre, Amsterdam, The Netherlands.
Eye (London, England)
|January 1, 1992
Summary
Sezolamide, a topical carbonic anhydrase inhibitor, significantly lowered intraocular pressure in glaucoma patients already using timolol. This add-on therapy demonstrated superior ocular hypotensive effects compared to placebo.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Elevated intraocular pressure (IOP) is a risk factor for glaucoma progression.
- Topical timolol is a common treatment for elevated IOP.
- Additional IOP-lowering agents are often needed for patients inadequately controlled on monotherapy.
Purpose of the Study:
- To evaluate the efficacy of sezolamide as an adjunctive therapy to timolol in patients with elevated IOP.
- To assess the ocular hypotensive activity of sezolamide in patients with primary open-angle glaucoma or ocular hypertension on continuing timolol therapy.
Main Methods:
- A three-center, double-masked, randomized, placebo-controlled, parallel study.
- 36 patients with bilateral primary open-angle glaucoma or ocular hypertension on 0.5% timolol twice daily were enrolled.
- Sezolamide 1.8% or placebo was added to timolol therapy for 2 weeks, with IOP measured over 12-hour diurnal curves and at specific time points.
Main Results:
- Patients receiving sezolamide plus timolol showed additional IOP reductions of 8.0% to 15.5% compared to baseline (timolol alone), which were statistically significant.
- Significantly greater IOP reductions were observed at 1, 2, 4, and 8 hours in the sezolamide group compared to the placebo group.
Conclusions:
- Sezolamide, when added to timolol, provides a significant additional IOP-lowering effect in patients with primary open-angle glaucoma or ocular hypertension.
- Sezolamide is an effective adjunctive treatment for managing elevated intraocular pressure.